Replimune Group Inc is a biotechnology company focused on developing innovative therapies for cancer treatment using its proprietary oncolytic virus platform. By harnessing genetically engineered viruses that selectively target and destroy cancer cells while stimulating the body’s immune system, Replimune aims to revolutionize the approach to cancer care. The company's research and development efforts are centered on creating novel therapeutic options that can potentially provide more effective and less toxic alternatives to traditional cancer treatments. Through their commitment to scientific advancement, Replimune is poised to make significant contributions to the field of oncology. Read More
Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Replimune Group, Inc. (NASDAQ: REPL) and certain of the Company’s senior executives for potential violations of the federal securities laws.
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Replimune To Contact Him Directly To Discuss Their Options
The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Replimune Group, Inc. (“Replimune” or “the Company”) (NASDAQ: REPL) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Rosen Law Firm, a global investor rights law firm, announces it has filed a class action lawsuit on behalf of purchasers of the securities of Replimune Group, Inc. (NASDAQ: REPL) between November 22, 2024 and July 21, 2025, both dates inclusive (the “Class Period”). The lawsuit seeks to recover damages for Replimune investors under the federal securities laws.
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Replimune (REPL) To Contact Him Directly To Discuss Their Options
NEW YORK, July 23, 2025 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP is investigating potential claims against Replimune Group, Inc. (“Replimune” or the “Company”) (NASDAQ:REPL). The investigation concerns whether Replimune and/or certain of its officers have violated the federal securities laws and/or engaged in other unlawful business practices.
Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Replimune Group, Inc. (“Replimune or the “Company”) (NASDAQ: REPL).
Wondering how the US markets performed one hour before the close of the markets on Tuesday? Discover the movers and shakers of today's session in our comprehensive analysis.
Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into Replimune Group, Inc. (NASDAQ: REPL) for potential violations of the federal securities laws.
Let's have a look at what is happening on the US markets in the middle of the day on Tuesday. Below you can find the top gainers and losers in today's session.
Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Replimune Group, Inc. (NASDAQ: REPL) resulting from allegations that Replimune may have issued materially misleading business information to the investing public.
The session on Tuesday is off to an intriguing start with several stocks showing significant price gaps. Let's examine the gap up and gap down stocks in today's session.
The US market is yet to commence its session on Tuesday, but let's get a preview of the pre-market session and explore the top gainers and losers driving the early market movements.
